Because MDM2 SNP309G and TP53 SNP72Arg have been reported to act synergistically and were together associated with the lowest age of cancer onset in carriers [10], we examined whether these variants may act together in sporadic RMS to confer increased risk of cancer onset at a younger age (Table 4). This evidence concerns the gene TP53 and cancer.